
CSL Reports Promising Four-Year Data on Gene Therapy for Hemophilia B
KING OF PRUSSIA, PA — CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb), the …
CSL Reports Promising Four-Year Data on Gene Therapy for Hemophilia B Read More